CTOs on the Move

Resilience Technology Corporation

www.resilience.com

 
Resilience is changing the way medicine is made – leveraging innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Robert Brown
Senior Director of Cyber Resilience Profile
Michael Good
Director Security Operations Profile
Brandy Duso
Director of Compliance and Risk Profile
Bill Reid
CISO and VP, Security and Privacy Profile
Chris Taylor
Senior Director Information Technology Profile

Funding

Resilience Technology Corporation raised $750M on 11/23/2020
Resilience Technology Corporation raised $625M on 06/06/2022

Similar Companies

Target RWE Health Evidence Solutions

At Target RWE, we are redefining and revolutionizing the generation and delivery of real-world evidence. Contact us today!

northcoast medical

northcoast medical is a Morgan Hill, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kailos Genetics

Kailos Genetics, the maker of Praxis, provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions through identifying risks to common medications. Praxis is an easily accessible form of personalized medicine catered to your lifestyle.

General Automation Lab Technologies

General Automation Lab Technologies (GALT), a San Francisco-based life science company, is developing advanced products to help researchers and companies cultivate and study bacteria and other microbes.

Myovant

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women`s health diseases and other endocrine-related disorders. Myovant`s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women`s health and endocrine-related disorders.